Navigation Links
Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial Results
Date:3/26/2013

HAYWARD, Calif., March 26, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), today announced financial results and business highlights for the quarter and fiscal year ended December 31, 2012.

Fourth Quarter and Fiscal Year 2012 Financial Results:

Total operating expenses for the fourth quarter ended December 31, 2012 were $8.1 million, as compared to $11.1 million for the third quarter ended September 30, 2012. The decrease in operating expenses for the period is related primarily to the reduced clinical activity following the completion of the PEARL-SC study.

Total operating expenses for the fiscal year ended December 31, 2012 were $55.9 million, as compared to $93.1 million for the fiscal year ended December 31, 2011. The decrease in operating expenses for the period can be attributed to the reduced clinical activity following the completion of the PEARL-SC study and the termination of the VISTA-16 study in early 2012.  

Anthera ended the fourth quarter of 2012 with approximately $24.8 million in cash and cash equivalents and short-term investments. On January 30, 2013, the Company completed a public offering of shares of its common stock resulting in net proceeds of approximately $43.0 million from the sale of 69,696,970 shares, which includes 9,090,909 shares issued upon the exercise in full of the underwriters' over-allotment option.

The Company intends to host a conference call during the second quarter of 2013 to provide an update on the Company's clinical development plan.

Recent Management Update:

Sanford Zweifach has been appointed to Anthera's Board of Directors.  Mr. Zweifach has over 20 years of extensive experience in the areas of corporate partnering, business development, operational and P&L experience, private and public investing and capital-raising in the life sciences industry. He currently serves as the Chief Executive Officer of Ascendancy Healthcare, Inc.  From 2005 until mid-2011, Mr. Zweifach was a Partner at Reedland Capital Partners, a boutique investment bank, where he headed its life sciences M&A and advisory efforts. Prior to joining Reedland, he was the CEO of Pathways Diagnostics, a biomarker development company. From 1997 to 2004 he was a Managing Director/CFO of Bay City Capital.  He received his BA in Biology from UC San Diego and holds an MS in Human Physiology from UC Davis.

"I am excited to welcome Sandy to the Anthera Board of Directors," said Dr. Christopher Henney , Ph.D., Anthera's Chairman of the Board. "His extensive expertise in commercial development and pharmaceutical transactions will be invaluable as we continue to move forward with the development of blisibimod."

About Anthera PharmaceuticalsAnthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune disorders.

Safe Harbor Statement

Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," "project," or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on Anthera's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially as set forth in Anthera's public filings with the SEC, including Anthera's Annual Report on Form 10-K for the year ended December 31, 2011 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2012.  Anthera disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.

CONTACT: Bianca Nery of Anthera Pharmaceuticals, Inc., bnery@anthera.com or 510.856.5586.ANTHERA PHARMACEUTICALS, INC.A Development Stage CompanySTATEMENT OF OPERATIONS(unaudited)(in thousands except share and per share data)Three Months Ended Dec 31,Twelve Months Ended Dec 31,2012201120122011OPERATING EXPENSE:  Research and development

$
7,089$
26,832$
49,219$
85,281  General and administrative

1,0001,5976,7157,857Total operating expense

8,08928,42955,93493,138LOSS FROM OPERATIONS:

(8,089)(28,429)(55,934)(93,138)OTHER (EXPENSE)/INCOME:Other (expense) income

(27)185(111)606Interest expense

(797)(912)(3,354)(2,803)Total other income (expense)

(824)(727)(3,465)(2,197)NET LOSS

$  (8,913)$   (29,156)$  (59,399)$   (95,335)Net loss per share--basic and diluted

$
(0.11)$
(0.71)$
(1.03)$
(2.55) Weighted-average number of shares used in per share calculation-- basic and diluted

79,120,94040,916,66657,803,49137,417,775 

 ANTHERA PHARMACEUTICALS, INC.A Development Stage CompanyBALANCE SHEET DATA(unaudited)(in thousands except share amounts)December 31,
2012December 31,
2011Cash and cash equivalents

$
9,431$
5,624Short term investments

$
5,322$
,746Total assets

$
26,445$
9,493Total current liabilities, excluding current portion of notes payable

$
9,421$
26,078Total notes payable

$
20,550$
24,331Deficit accumulated during development stage

$  (260,378)$  (200,979)Total shareholders' equity(deficit)

$
(3,526)$
9,084Common shares outstanding

79,151,59240,933,354 


'/>"/>
SOURCE Anthera Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Anthera Pharmaceuticals Reports 2012 Third Quarter Financial Results And Provides Clinical Progress Update
2. Anthera to Report Second Quarter 2012 Financial Results
3. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2012 Financial Results
4. New Opportunity: The Biomedical Innovations of Tomorrow - Research Report on PhotoMedex, Axiall Corp, Varian Medical Systems, Volcano Corporation and Navidea Biopharmaceuticals
5. Keryx Biopharmaceuticals to Present at the 25th Annual ROTH Conference
6. Regeneron Pharmaceuticals’ Industrial Operations & Product Supply Site Receives International Recognition for Operational Excellence
7. Leica Biosystems and Synthon Biopharmaceuticals Partner to Develop a Companion Diagnostic Program for Targeted Cancer Therapies
8. Radiopharmaceuticals Market - Global Industry Analysis, Size, Share, Trends And Forecast, 2012 - 2018: MarketResearchReports.Biz
9. Alexandria Real Estate Equities, Inc. Announces Long-Term Lease with Leading Global Commercial-Stage Oncology Company, Onyx Pharmaceuticals, Inc., for New Build-to-Suit Facility in South San Francisco, California
10. AVANIR Pharmaceuticals To participate in two conferences in March
11. Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2012 Financial Results and Guidance for 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... OXFORD, England , Aug. 16, 2017  Kingfisher ... executive search and leadership development, and Virdis Group, global executive ... an exclusive alliance that enables clients to leverage the expertise ... "For our clients here in the Boston ... a diverse population of leadership talent throughout the US, ...
(Date:8/15/2017)... ... August 15, 2017 , ... Nanomedical Diagnostics ... biotherapeutics development, announces the launch of the new NHS Agile biosensor chip ... binding data for a wide range of molecules, including small and large molecules, ...
(Date:8/15/2017)... Kenosha, Wisconsin (PRWEB) , ... August 15, 2017 ... ... introduced a new family of 6” modular downlights designed to stay tightly sealed ... applications, including areas where damp and wet location listings just aren't enough, such ...
(Date:8/15/2017)... Allentown, PA (PRWEB) , ... August 15, 2017 ... ... and encrypted shopping cart. Now mobile responsive, the new website makes it ... lab or anywhere in between. Users can now find detailed product information, educational ...
Breaking Biology Technology:
(Date:5/16/2017)... TEANECK, N.J. , May 16, 2017  Veratad ... leading provider of online age and identity verification solutions, ... the K(NO)W Identity Conference 2017, May 15 thru May ... Ronald Regan Building and International Trade Center. ... across the globe and in today,s quickly evolving digital ...
(Date:4/18/2017)... , April 18, 2017  Socionext Inc., a global expert in ... media edge server, the M820, which features the company,s hybrid codec ... provided by Tera Probe, Inc., will be showcased during the upcoming ... NAB show at the Las Vegas Convention ... Click ...
(Date:4/11/2017)... Apr. 11, 2017 Research and Markets has ... report to their offering. ... The global eye tracking market to grow at a CAGR of ... Eye Tracking Market 2017-2021, has been prepared based on an in-depth ... market landscape and its growth prospects over the coming years. The ...
Breaking Biology News(10 mins):